XOMA Royalty (XOMA) Cash from Investing Activities (2010 - 2026)
XOMA Royalty (XOMA) reported Cash from Investing Activities of $6.6 million for Q1 2026, up 197.89% on a YoY basis from $2.2 million in Q1 2025, and down 66.13% sequentially from $19.3 million in Q4 2025.
XOMA Royalty (XOMA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Cash from Investing Activities data on file, last reported at $6.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 197.89% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at -$775000.0 (up 97.2% YoY), and the FY2025 full-year result was $50.9 million, up 280.07% from the prior year.
- Cash from Investing Activities fell to $6.6 million in Q1 2026, from $19.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $19.3 million in Q4 2025 to a low of -$36.4 million in Q4 2024.
- A 5-year average of -$3.3 million and a median of -$4.5 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 21030.77% in 2023 and tumbled 761.06% in 2024, its largest moves.
- Tracing XOMA's Cash from Investing Activities over 5 years: stood at -$15.2 million in 2022, then surged by 136.14% to $5.5 million in 2023, then plunged by 761.06% to -$36.4 million in 2024, then jumped by 153.11% to $19.3 million in 2025, then plunged by 66.13% to $6.6 million in 2026.
- Business Quant data shows XOMA's Cash from Investing Activities at $6.6 million in Q1 2026, $19.3 million in Q4 2025, and -$20.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 6.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.55 Mn |
| Mar 31, 2026 | 6.55 Mn |
| Dec 31, 2025 | 19.35 Mn |
| Dec 31, 2025 | 19.35 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -6.69 Mn |
| Mar 31, 2025 | -6.69 Mn |
| Dec 31, 2024 | -36.43 Mn |
| Dec 31, 2024 | -36.43 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2024 | -7.25 Mn |
| Mar 31, 2024 | -7.25 Mn |
| Dec 31, 2023 | 5.51 Mn |
| Dec 31, 2023 | 5.51 Mn |
| Sep 30, 2023 | 5.49 Mn |
| Sep 30, 2023 | 5.49 Mn |